Ivermectin: Can it be a potential therapy for COVID-19 prophylaxis?
5 min55
Frequent headaches while looking at the screen.....
Frequent headaches while looking at the screen.....
Frequent headaches while looking at the screen.....
Frequent headaches while looking at the screen.....
Frequent headaches while looking at the screen.....
Lorem ipsum dolor sit amet, consectetur adipiscing
elit, sed
do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim
ad minim
veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea
commodo
consequat.
Duis aute irure dolor in reprehenderit in voluptate
velit esse
cillum dolore eu fugiat nulla pariatur. Excepteur sint occaecat
cupidatat non
proident, sunt in culpa qui officia deserunt mollit anim id est laborum.
The coronavirus disease 2019
(COVID-19), caused by severe acute respiratory syndrome coronavirus 2
(SARS-CoV-2) has led to a rush to repurpose existing drugs for managing the
infected patients.
This study aimed to evaluate the outcome of the second bDMARD (non-TNFi i.e rituximab, abatacept or tocilizumab, used individually) and TNFi) following the stop...
You want to delete this comment?Please mention commentInvalid Text ContentText Content cannot me more than 1000Something Went WrongCancelConfirmConfirm DeleteHide RepliesViewRepliesView Repliesenruua
Try:
This website uses cookies to help us give you the best experience when you visit.
By using this website you consent to our use of cookies. For more information please review our cookie policy.
Comments (0)